Related Experiment Video

Updated: Aug 16, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Invasive pulmonary aspergillosis

S R Doffman1, S G Agrawal, Jeremy S Brown

  • 1Barts & the London NHS Trust, West Smithfield, London, EC1A 7BE, UK. s.doffman@qmul.ac.uk

Expert Review of Anti-Infective Therapy
|August 19, 2005
PubMed

Insights

Invasive aspergillosis is a serious fungal infection with high mortality. New diagnostic tools and antifungal drugs like voriconazole offer improved treatment options and hope for better patient outcomes.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • Invasive aspergillosis presents a significant clinical challenge with high mortality rates (up to 80%) in susceptible individuals.
  • Early diagnosis of invasive aspergillosis is difficult, often leading to empirical antifungal treatment with associated costs and toxicities.
  • Limited effective antifungal agents were available until recently, complicating the management of this severe infection.

Purpose of the Study:

  • To highlight the challenges in diagnosing and treating invasive aspergillosis.
  • To discuss the impact of new antifungal agents and diagnostic techniques on patient outcomes.
  • To provide an outlook on the future management of invasive aspergillosis.

Main Methods:

  • Review of current clinical practices and therapeutic options for invasive aspergillosis.
  • Discussion of recent advancements in microbiologic diagnostic techniques.
  • Analysis of the role of novel antifungal drugs, including voriconazole and caspofungin.

Main Results:

  • Introduction of voriconazole and caspofungin has expanded treatment choices for invasive aspergillosis.
  • Advancements in microbiologic techniques are improving early diagnosis capabilities.
  • These combined advances offer potential for significant reductions in morbidity and mortality.

Conclusions:

  • Newer antifungal therapies and improved diagnostics represent a hopeful advancement in managing invasive aspergillosis.
  • The combination of effective drugs and earlier detection is expected to improve patient survival and reduce disease burden.
  • Continued research and implementation of these advancements are crucial for better patient outcomes in the coming years.

More Related Videos

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

Related Concept Videos

Fungal Phylum Ascomycota01:28

Fungal Phylum Ascomycota

Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...